Your browser doesn't support javascript.
loading
Long-term outcome of GIST patients treated with delayed imatinib therapy.
Kurtovic-Kozaric, Amina; Kugic, Amina; Hasic, Azra; Beslija, Semir; Ceric, Timur; Pasic, Anes; Vranic, Semir; Kopric, Dijana; Iljazovic, Ermina; Todorovic Barbuscia, Jelena; Kozaric, Mirza; Ibisevic, Nermina; Keskic, Leila; Kurtovic, Sabira.
Afiliación
  • Kurtovic-Kozaric A; Department of Pathology, Cytology and Human Genetics, Clinical Center of the University of Sarajevo, Sarajevo, Bosnia and Herzegovina; Department of Genetics, Section of Biology, Faculty of Natural Sciences and Mathematics, University of Sarajevo, Sarajevo, Bosnia and Herzegovina. Electronic address
  • Kugic A; Department of Genetics, Section of Biology, Faculty of Natural Sciences and Mathematics, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
  • Hasic A; Department of Genetics, Section of Biology, Faculty of Natural Sciences and Mathematics, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
  • Beslija S; Department of Oncology, Clinical Center of the University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
  • Ceric T; Department of Oncology, Clinical Center of the University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
  • Pasic A; Department of Oncology, Clinical Center of the University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
  • Vranic S; Department of Pathology, Cytology and Human Genetics, Clinical Center of the University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
  • Kopric D; Oncology Clinic, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina.
  • Iljazovic E; Department of Pathology, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina.
  • Todorovic Barbuscia J; Department of Pathology, Cytology and Forensic Medicine, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina.
  • Kozaric M; Department of Genetics, Section of Biology, Faculty of Natural Sciences and Mathematics, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
  • Ibisevic N; Department of Pathology, Cytology and Human Genetics, Clinical Center of the University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
  • Keskic L; Department of Genetics and Bioengineering, International Burch University, Sarajevo, Bosnia and Herzegovina.
  • Kurtovic S; Hematology Clinic, Clinical Center of the University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
Eur J Cancer ; 78: 118-121, 2017 06.
Article en En | MEDLINE | ID: mdl-28437709
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tumores del Estroma Gastrointestinal / Tiempo de Tratamiento / Mesilato de Imatinib Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Eur J Cancer Año: 2017 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tumores del Estroma Gastrointestinal / Tiempo de Tratamiento / Mesilato de Imatinib Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Eur J Cancer Año: 2017 Tipo del documento: Article Pais de publicación: Reino Unido